Vectibix is used on its own in patients whose tumour cells have a protein on their surface called the epidermal growth factor receptor (EGFR) and which contain a non-mutated ‘ KRAS’.
Vectibixi kasutatakse ainuravimina patsientidel, kelle kasvajarakkude pinnal on valku, mida nimetatakse epidermaalse kasvuteguri retseptoriks (EGFR) ja kelle kasvajarakud sisaldavad muteerumata KRAS- geeni.